Clinical trial
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
NCT00472030 · University of Iowa, Other · Completed
Key facts
| NCT number | NCT00472030 |
|---|---|
| Title | Efficacy and Safety of Omalizumab in Bullous Pemphigoid |
| Official title | An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid |
| Lead sponsor | University of Iowa, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bullous Pemphigoid |
| Intervention type | Drug |
| Interventions | Omalizumab, prednisone |
| Enrollment | 2 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | May 10, 2007 |
| Last update posted | Oct 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: